Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet age-related macular degeneration (AMD), a leading cause of blindness in the elderly.
Regeneron’s shares fell 3.6 percent, and were the biggest drag on the Nasdaq biotech index. Shares of Ophthotech Corp, which is evaluating combinations of its experimental drug with Eylea or rival drugs, also fell.
Source: Reuters
Filed Under: Drug Discovery
